BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Our core commitment centers on advancing R and D and Clinical 
 Development strategies for TCR therapies\, aiming to harness their immens
 e potential in targeting solid tumors. These therapies offer promising av
 enues for enhancing treatment methodologies\, thereby fostering optimism 
 for improved outcomes among patients grappling with these challenging con
 ditions.\n\nThe recent submission of a Biologics License Application (BLA
 ) by Adaptimmune is a remarkable milestone\, signifying remarkable progre
 ss in gaining regulatory approval for their TCR-based cancer therapy. Thi
 s achievement indicates a pivotal step forward\, paving the way for broad
 er accessibility of this innovative treatment to patients in critical nee
 d.\n\nThe 5th TCR-based Therapies for Solid Tumors Summit returns as your
  only meeting where TCR pipelines have the center stage\, serving as your
  ultimate platform to network with the most senior industry leaders in bi
 opharma dedicated to accelerating clinical and commercial development of 
 TCR-based therapeutics.\n\nTime: 9:00 AM - 5:30 PM\n\nURLs:Tickets: https
 ://go.evvnt.com/2147535-2?pid=185Brochure: https://go.evvnt.com/2147535-3
 ?pid=185\n\nSpeakers: Alfred Lim\, Head of Pipeline Research\, Etcembly\,
  Andrew Bayliffe\, Chief Scientific Officer\, Marengo Therapeutics\, Caga
 n Gurer\, Vice President Disovery\, TScan Therapeutics\, Casey Bermack\, 
 Oncology Fellow\, MD Anderson Cancer Center\, Cassian Yee\, Professor\, D
 epartment of Immunology and Department of Melanoma Medical Oncology\, MD 
 Anderson Cancer Center\, Chengbin Wu\, Chief Executive Officer\, EpiMab\,
  Dan MacLeod\, Vice President - Discovery\, Immunoscape\, David Dilillo\,
  Senior Director\, Immuno-Oncology\, Regeneron\, Debora Barton\, Chief Me
 dical Officer\, TScan Therapeutics\, E-Chiang Lee\, Executive Vice Presid
 ent - Research\, T Therapeutics\, Gavin MacBeath\, Chief Executive Office
 r\, TScan Therapeutics\, Geraldine Paulus\, Co-Founder\, Vice President o
 f Corporate Development and Operations\, Crossbow Technology\, Hubert Lam
 \, Vice President - Preclinical Development\, Affini-T Therapeutics\, Ina
 n Edes\, Scientist and Co-Founder\, Chief Executive Officer\, Captain T C
 ell\, Kenneth LaMontagne\, Chief Business Officer\, Zelluna Immunotherapy
 \, Leonardo Borras\, Chief Scientific Officer\, CDR Life\, Michael Lehmic
 ke\, Senior Vice President\, Science and Industry Affairs\, Alliance for 
 Regenerative Medicine\, Michael Platten\, Co-Founder\, TcellTech\, Peggy 
 Sotiropoulou\, Chief Scientific Officer\, T-knife Therapeutics\, Reagan J
 arvis\, Chief Executive Officer\, Anocca\, Richard Harbottle\, Head of DN
 A Vector Research Group\, DKFZ\, Rodrigo Vazquez-Lombardi\, Chief Scienti
 fic Officer\, Engimmune\, Scott Norberg\, Head of Solid Tumor Therapy Gro
 up\, National Cancer Institute (NCI)\, Shannon Oda\, Principal Investigat
 or\, Seattle Children's Hospital\, Shawn P Kubli\, Co-Founder\, Director 
 of Cell Therapy\, Treadwell Therapeutics\, Stewart Abbot\, Chief Scientif
 ic Officer\, Turnstone Therapeutics\, Thomas Andresen\, Chief Executive O
 fficer\, T-Cypher Bio\, Wendell Yang\, President and Founder\, Imgen BioS
 ciences\, Yanyan Han\, Chief Scientific Officer\, HRYZ\, Zhen Su\, Chief 
 Executive Officer\, Marengo Therapeutics\n
DTEND:20240425T173000
DTSTAMP:20260512T213555Z
DTSTART:20240423T090000
LOCATION:Hilton Boston Back Bay\, 40\, 40 Dalton Street\, Boston\, Massach
 usetts\, 02115\,
SEQUENCE:0
SUMMARY:Our core commitment centers on advancing R and D and Clinical Deve
 lopment strategies for TCR therapies\, aiming to harness their immense po
 tential i...
UID:7e56b490-8cf7-406c-94be-604a29357c3d
END:VEVENT
END:VCALENDAR